ResultsIQ

ResultsIQ › Latest results › Bodal Chemicals Limited

Bodal Chemicals Limited Q4 FY25 earnings call summary

NSE: BODALCHEM · BSE: 524370

Earnings call of 29 May 2025, summarised by AI from the filing.

₹120 cr to ₹150 cr debt reduction targeted in current year, including ₹20 cr from land sale.

Key takeaways

  1. Debt reduction ₹120 cr to ₹150 cr debt reduction targeted in current year, including ₹20 cr from land sale.
  2. Benzene demand Paracetamol industry utilisation around 50%, main consumer; margin under pressure from competition and slow demand.

Original filing on BSE

Bodal Chemicals Limited Q1 FY27 results

As filed: Revenue ₹709 cr (+56% year on year), EBITDA ₹68.9 cr (+41% year on year), PAT ₹30.4 cr (+204% year on year), EBITDA margin 9.7% (−107 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹588 cr (+30% year on year), EBITDA ₹68.6 cr (+43% year on year), PAT ₹32.1 cr (+114% year on year), EBITDA margin 11.7% (+102 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 102 bps year on year. Tax rate 11%. Revenue rose ₹137 cr on a year ago, more than the ₹57.0 cr it added the year before. Share price after the results: +2.9% in 29 days (Nifty 500: +2.5%).
  • Q3 FY26: Revenue ₹490 cr (+11% year on year), EBITDA ₹22.1 cr (−50% year on year), PAT ₹0.2 cr (−95% year on year), EBITDA margin 4.5% (−543 bps). Score 14 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 543 bps year on year. Other income 6288% of PBT. Tax rate 0%. Profit fell 96% from last quarter. Share price after the results: −12.4% in 30 days (Nifty 500: −7.8%).
  • Q2 FY26: Revenue ₹480 cr (+12% year on year), EBITDA ₹23.0 cr (−30% year on year), PAT ₹6.0 cr, EBITDA margin 4.8% (−290 bps). Score 12 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 290 bps year on year. Other income 333% of PBT. Tax rate 0%. Profit fell 40% from last quarter. Share price after the results: −12.1% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹454 cr (+8% year on year), EBITDA ₹49.0 cr (+40% year on year), PAT ₹10.0 cr, EBITDA margin 10.8% (+250 bps). Score 37 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 250 bps year on year. Other income 31% of PBT. Profit fell 33% from last quarter. Share price after the results: −2.6% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹451 cr (+14% year on year), EBITDA ₹48.0 cr (+85% year on year), PAT ₹15.0 cr (+300% year on year), EBITDA margin 10.6% (+404 bps). Score 65 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 404 bps year on year. Tax rate -25%. Share price after the results: −3.7% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹443 cr (+31% year on year), EBITDA ₹44.0 cr (+83% year on year), PAT ₹5.0 cr (+300% year on year), EBITDA margin 9.9% (+285 bps). Score 82 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit before exceptional items growth were well above it. EBITDA margin rose 285 bps year on year. Tax rate 38%.
  • Q2 FY25: Revenue ₹429 cr (+30% year on year), EBITDA ₹33.0 cr (+43% year on year), PAT ₹0.0 cr (−100% year on year), EBITDA margin 7.7% (+72 bps). Score 20 of 100, Below trend. EBITDA margin rose 72 bps year on year. Other income 500% of PBT. Tax rate 100%. Consolidated profit -100% but standalone +0%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Bodal Chemicals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.